All Work

Trey Thoelcke

After Microsoft’s Q1 Slide, Are the Bulls Still On Board?

Microsoft (NASDAQ: MSFT | MSFT Price Prediction) was last seen trading near $373, while the average analyst price target sits at $587.31. That gap exceeds 57%, a dislocation that demands explanation. The stock has…

Trey Thoelcke · 6 months ago

Is Coca-Cola Paying More in Dividends Than It Can Afford?

Coca-Cola (NYSE: KO | KO Price Prediction) delivered its Q1 2026 dividend of $0.53 per share to shareholders on April 1, 2026, marking another milestone in one of the most unbroken dividend growth streaks…

Trey Thoelcke · 6 months ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative…

Trey Thoelcke · 6 months ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each offering a…

Trey Thoelcke · 6 months ago